BioRestorative Therapies (BRTX) Non Operating Income (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Non Operating Income came in at $617664.0 in Q4 2025, down 41.4% YoY from $1.1 million in Q4 2024, and down 7.91% on a QoQ basis from $670734.0 in Q3 2025.
BioRestorative Therapies (BRTX) Non Operating Income (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Non Operating Income data on file, last reported at $617664.0 in Q4 2025.
- Quarterly Non Operating Income fell 41.4% year-over-year to $617664.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 45.45% YoY) and the FY2025 annual result came in at $1.4 million, down 45.45% from the prior year.
- Non Operating Income retreated to $617664.0 in Q4 2025, from $670734.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $9.5 million in Q4 2022 to a low of -$16.4 million in Q4 2021.
- A 5-year average of -$33635.2 and a median of $659879.0 in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 1423.42% — and 2023, when it jumped 840.76%.
- Tracing BRTX's Non Operating Income over 5 years: stood at -$16.4 million in 2021, then soared by 157.89% to $9.5 million in 2022, then sank by 90.34% to $916688.0 in 2023, then climbed by 14.98% to $1.1 million in 2024, then tumbled by 41.4% to $617664.0 in 2025.
- The last three Non Operating Income figures came in at $617664.0 (Q4 2025), $670734.0 (Q3 2025), and $649024.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 617,664.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 617,664.00 |
| Sep 30, 2025 | 670,734.00 |
| Jun 30, 2025 | 649,024.00 |
| Mar 31, 2025 | -532,265.00 |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 916,688.00 |
| Sep 30, 2023 | 7.87 Mn |
| Jun 30, 2023 | -2.59 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 9.49 Mn |
| Sep 30, 2022 | 836,848.00 |
| Jun 30, 2022 | -7.73 Mn |
| Mar 31, 2022 | 3.15 Mn |
| Dec 31, 2021 | -16.39 Mn |
| Sep 30, 2021 | -495,545.00 |
| Jun 30, 2021 | -507,332.00 |
| Mar 31, 2021 | -598,674.00 |